240 related articles for article (PubMed ID: 28904234)
1. Fibrin Clot Permeability as a Predictor of Stroke and Bleeding in Anticoagulated Patients With Atrial Fibrillation.
Drabik L; Wołkow P; Undas A
Stroke; 2017 Oct; 48(10):2716-2722. PubMed ID: 28904234
[TBL] [Abstract][Full Text] [Related]
2. Relation of the HAS-BLED bleeding risk score to major bleeding, cardiovascular events, and mortality in anticoagulated patients with atrial fibrillation.
Gallego P; Roldán V; Torregrosa JM; Gálvez J; Valdés M; Vicente V; Marín F; Lip GY
Circ Arrhythm Electrophysiol; 2012 Apr; 5(2):312-8. PubMed ID: 22319005
[TBL] [Abstract][Full Text] [Related]
3. The HAS-BLED score has better prediction accuracy for major bleeding than CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation.
Roldán V; Marín F; Manzano-Fernández S; Gallego P; Vílchez JA; Valdés M; Vicente V; Lip GY
J Am Coll Cardiol; 2013 Dec; 62(23):2199-204. PubMed ID: 24055744
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Previous Stroke or Transient Ischemic Attack.
Coleman CI; Peacock WF; Bunz TJ; Alberts MJ
Stroke; 2017 Aug; 48(8):2142-2149. PubMed ID: 28655814
[TBL] [Abstract][Full Text] [Related]
5. Clot Lysis Time Predicts Stroke During Anticoagulant Therapy in Patients with Atrial Fibrillation.
Drabik L; Konieczyńska M; Undas A
Can J Cardiol; 2020 Jan; 36(1):119-126. PubMed ID: 31740169
[TBL] [Abstract][Full Text] [Related]
6. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score.
Lip GY; Frison L; Halperin JL; Lane DA
J Am Coll Cardiol; 2011 Jan; 57(2):173-80. PubMed ID: 21111555
[TBL] [Abstract][Full Text] [Related]
7. Three-month risk-benefit profile of anticoagulation after stroke with atrial fibrillation: The SAMURAI-Nonvalvular Atrial Fibrillation (NVAF) study.
Arihiro S; Todo K; Koga M; Furui E; Kinoshita N; Kimura K; Yamagami H; Terasaki T; Yoshimura S; Shiokawa Y; Kamiyama K; Takizawa S; Okuda S; Okada Y; Nagakane Y; Kameda T; Hasegawa Y; Shibuya S; Ito Y; Nakashima T; Takamatsu K; Nishiyama K; Matsuki T; Homma K; Takasugi J; Tokunaga K; Sato S; Kario K; Kitazono T; Toyoda K;
Int J Stroke; 2016 Jul; 11(5):565-74. PubMed ID: 26927811
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of SAMe-TT2R2 risk score for predicting the quality of anticoagulation control in a real-world cohort of patients with non-valvular atrial fibrillation on vitamin-K antagonists.
Abumuaileq RR; Abu-Assi E; Raposeiras-Roubin S; López-López A; Redondo-Diéguez A; Álvarez-Iglesias D; Rodríguez-Mañero M; Peña-Gil C; González-Juanatey JR
Europace; 2015 May; 17(5):711-7. PubMed ID: 25662984
[TBL] [Abstract][Full Text] [Related]
9. Elevated NT-proBNP is associated with unfavorably altered plasma fibrin clot properties in atrial fibrillation.
Matusik PT; Matusik PS; Kornacewicz-Jach Z; Małecka B; Ząbek A; Undas A
Int J Cardiol; 2017 Sep; 243():244-250. PubMed ID: 28571619
[TBL] [Abstract][Full Text] [Related]
10. Lysability of fibrin clots is a potential new determinant of stroke risk in atrial fibrillation.
Skov J; Sidelmann JJ; Bladbjerg EM; Jespersen J; Gram J
Thromb Res; 2014 Sep; 134(3):717-22. PubMed ID: 25042725
[TBL] [Abstract][Full Text] [Related]
11. Denser plasma clot formation and impaired fibrinolysis in paroxysmal and persistent atrial fibrillation while on sinus rhythm: association with thrombin generation, endothelial injury and platelet activation.
Drabik L; Wołkow P; Undas A
Thromb Res; 2015 Aug; 136(2):408-14. PubMed ID: 26048399
[TBL] [Abstract][Full Text] [Related]
12. Safety of Anticoagulation in Patients Treated With Urgent Reperfusion for Ischemic Stroke Related to Atrial Fibrillation.
Giustozzi M; Acciarresi M; Agnelli G; Caso V; Bandini F; Tsivgoulis G; Yaghi S; Furie KL; Tadi P; Becattini C; Zedde M; Abdul-Rahim AH; Lees KR; Alberti A; Venti M; D'Amore C; Giulia Mosconi M; Anna Cimini L; Bovi P; Carletti M; Rigatelli A; Cappellari M; Putaala J; Tomppo L; Tatlisumak T; Marcheselli S; Pezzini A; Poli L; Padovani A; Vannucchi V; Sohn SI; Lorenzini G; Tassi R; Guideri F; Acampa M; Martini G; Ntaios G; Athanasakis G; Makaritsis K; Karagkiozi E; Vadikolias K; Liantinioti C; Theodorou A; Halvatsiotis P; Mumoli N; Galati F; Sacco S; Tiseo C; Corea F; Ageno W; Bellesini M; Silvestrelli G; Ciccone A; Lanari A; Scoditti U; Denti L; Mancuso M; Ferrari E; Ulivi L; Orlandi G; Giannini N; Tassinari T; Luisa De Lodovici M; Rueckert C; Baldi A; Toni D; Letteri F; Giuntini M; Maria Lotti E; Flomin Y; Pieroni A; Kargiotis O; Karapanayiotides T; Monaco S; Maimone Baronello M; Csiba L; Szabó L; Chiti A; Giorli E; Del Sette M; Imberti D; Zabzuni D; Doronin B; Volodina V; Michel P; Vanacker P; Barlinn K; Barlinn J; Deleu D; Gourbali V; Paciaroni M; Masotti L
Stroke; 2020 Aug; 51(8):2347-2354. PubMed ID: 32646335
[TBL] [Abstract][Full Text] [Related]
13. Thromboembolic events, bleeding, and drug discontinuation in patients with atrial fibrillation on anticoagulation: a prospective hospital-based registry.
Königsbrügge O; Simon A; Domanovits H; Pabinger I; Ay C
BMC Cardiovasc Disord; 2016 Dec; 16(1):254. PubMed ID: 27938343
[TBL] [Abstract][Full Text] [Related]
14. Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: The ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): Predictors, Characteristics, and Clinical Outcomes.
Hylek EM; Held C; Alexander JH; Lopes RD; De Caterina R; Wojdyla DM; Huber K; Jansky P; Steg PG; Hanna M; Thomas L; Wallentin L; Granger CB
J Am Coll Cardiol; 2014 May; 63(20):2141-2147. PubMed ID: 24657685
[TBL] [Abstract][Full Text] [Related]
15. Effect of suboptimal anticoagulation treatment with antiplatelet therapy and warfarin on clinical outcomes in patients with nonvalvular atrial fibrillation: A population-wide cohort study.
Chan EW; Lau WC; Siu CW; Lip GY; Leung WK; Anand S; Man KK; Wong IC
Heart Rhythm; 2016 Aug; 13(8):1581-8. PubMed ID: 27033342
[TBL] [Abstract][Full Text] [Related]
16. Vitamin K antagonists favourably modulate fibrin clot properties in patients with atrial fibrillation as early as after 3days of treatment: Relation to coagulation factors and thrombin generation.
Ząbczyk M; Majewski J; Karkowski G; Malinowski KP; Undas A
Thromb Res; 2015 Oct; 136(4):832-8. PubMed ID: 26319777
[TBL] [Abstract][Full Text] [Related]
17. Assays of fibrin network properties altered by VKAs in atrial fibrillation - importance of using an appropriate coagulation trigger.
Ząbczyk M; Blombäck M; Majewski J; Karkowski G; Wallen HN; Undas A; He S
Thromb Haemost; 2015 Apr; 113(4):851-61. PubMed ID: 25518887
[TBL] [Abstract][Full Text] [Related]
18. Elevated 8-isoprostane concentration is associated with thromboembolic events in patients with atrial fibrillation.
Mołek P; Chmiel J; Ząbczyk M; Malinowski KP; Natorska J; Undas A
Int J Cardiol; 2022 Oct; 365():1-7. PubMed ID: 35868355
[TBL] [Abstract][Full Text] [Related]
19. Prothrombotic State in Patients With a Left Atrial Appendage Thrombus of Unknown Origin and Cerebrovascular Events.
Meus R; Son M; Sobczyk D; Undas A
Stroke; 2016 Jul; 47(7):1872-8. PubMed ID: 27301942
[TBL] [Abstract][Full Text] [Related]
20. Genetic and Non-Genetic Factors Affecting the Quality of Anticoagulation Control and Vascular Events in Atrial Fibrillation.
Park YK; Lee MJ; Kim JH; Lee JS; Park RW; Kim GM; Chung CS; Lee KH; Kim JS; Lee SY; Bang OY
J Stroke Cerebrovasc Dis; 2017 Jun; 26(6):1383-1390. PubMed ID: 28412319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
